Does Blue Cross Blue Shield of Arizona Cover Liraglutide (Saxenda)?

What Is Liraglutide (Saxenda) and Why Does Coverage Vary?

Liraglutide 3 mg (Saxenda) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA in December 2014 specifically for chronic weight management in adults, and in 2020 for adolescents aged 12 to 17 with an initial body weight above 60 kg and obesity [1]. It is a distinct product from Victoza (liraglutide 1.2 to 1.8 mg), which carries a type 2 diabetes indication and is covered under different formulary rules.

Coverage varies because the Affordable Care Act does not mandate coverage of obesity pharmacotherapy for commercial plans the way it mandates coverage of, for example, preventive services. Each insurer designs its own drug benefit. BCBS Arizona offers multiple plan types, including fully insured commercial, self-funded employer plans, and ACA marketplace plans, and the drug benefit differs across each one.

The FDA-Approved Indication Matters for Payers

The FDA label states that Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia [1]. BCBS Arizona's prior authorization criteria typically mirror this language almost exactly. Prescribers who document a BMI outside these thresholds, or who fail to list a comorbidity when BMI is 27 to 29.9, face near-certain denial.

How GLP-1 Drugs Fit Into BCBS AZ Formularies

BCBS Arizona uses a tiered formulary. Saxenda most often lands on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) depending on the specific plan year and whether the plan has negotiated a preferred position for a competing GLP-1 agent such as semaglutide (Wegovy). Step therapy requirements, which force a trial of a lower-cost or preferred drug first, appear in some BCBS AZ plans and could require documentation that the member has already tried and failed an alternative anti-obesity medication before Saxenda is approved [2].

Prior Authorization Criteria for Saxenda Under BCBS AZ

Prior authorization (PA) is required for Saxenda under virtually all BCBS Arizona plan types that include a weight-management drug benefit. The PA process involves a formal clinical review, and denials are issued when documentation is incomplete.

Standard PA Requirements

Most BCBS AZ PA forms for obesity pharmacotherapy ask for all of the following items:

• Confirmed BMI at or above the FDA threshold, documented within the past 12 months with an in-office height and weight measurement
• Diagnosis code for obesity (E66.01 for morbid obesity due to excess calories, or E66.09 for other obesity) or overweight (E66.3) paired with a qualifying comorbidity diagnosis
• Documentation of a supervised, reduced-calorie diet and physical activity program lasting at least three months, with records showing inadequate weight loss (typically defined as less than five percent of initial body weight)
• Absence of contraindications listed in the FDA label, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or prior serious hypersensitivity reaction to liraglutide [1]
• Prescriber attestation that the drug will be used as an adjunct to behavioral intervention, not as monotherapy

The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity recommends that drug therapy be offered to patients who have not achieved their weight-loss goals through lifestyle intervention alone, which aligns with the three-month program documentation requirement above [3].

Step Therapy and Formulary Alternatives

Some BCBS AZ employer group plans impose step therapy requiring a trial of phentermine/topiramate (Qsymia) or bupropion/naltrexone (Contrave) before approving a GLP-1 agent. If your plan has this requirement, your prescriber must document either that those agents were tried and failed, or that a contraindication exists. The FDA label for phentermine/topiramate, for example, contraindicates its use in patients with hyperthyroidism or glaucoma, which are legitimate reasons to bypass step therapy [4].

Adolescent Coverage Nuances

For adolescents aged 12 to 17, the FDA approved liraglutide 3 mg in 2020 based on the SCALE Adolescents trial (N=251), in which liraglutide produced a mean BMI standard deviation score reduction of 0.22 versus 0.22 increase in the placebo group at 56 weeks [5]. BCBS AZ PA criteria for pediatric obesity pharmacotherapy often require documentation from a pediatric endocrinologist or obesity medicine specialist, not a general practitioner, before a PA is approved for a member under 18.

Clinical Evidence Supporting Liraglutide for Weight Loss

Payers evaluate clinical necessity against published evidence. Understanding the trial data your prescriber can cite strengthens a PA submission or appeal.

SCALE Obesity and Prediabetes Trial

The SCALE Obesity and Prediabetes trial (N=3,731) randomized adults with BMI of 30 or greater, or 27 or greater with dyslipidemia or hypertension, to liraglutide 3 mg or placebo for 56 weeks. Liraglutide produced a mean weight loss of 8.4 kg (8.0 percent) versus 2.8 kg (2.6 percent) with placebo [6]. At least five percent weight loss was achieved by 63.2 percent of liraglutide patients versus 27.1 percent with placebo (P<0.001) [6]. These numbers are the ones your prescriber should quote directly in a PA letter or appeal.

SCALE Diabetes Trial

In adults with type 2 diabetes, the SCALE Diabetes trial (N=846) showed that liraglutide 3 mg produced 6.0 percent mean weight loss at 56 weeks versus 2.0 percent with placebo [7]. Given that type 2 diabetes is one of the qualifying comorbidities for a BMI 27 to 29.9 indication, this trial is directly relevant to BCBS AZ PA submissions for patients in that BMI range.

Cardiovascular Data

The LEADER trial (N=9,340) evaluated liraglutide 1.8 mg (Victoza, the diabetes dose) in adults with type 2 diabetes at high cardiovascular risk. Liraglutide reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 13 percent versus placebo (hazard ratio 0.87, 95% CI 0.78 to 0.97, P=0.01 for superiority) [8]. While LEADER used the diabetes dose rather than the 3 mg obesity dose, insurers and prescribers cite it to justify GLP-1 therapy in high-cardiovascular-risk patients, and some BCBS AZ PA reviewers find it relevant when a patient carries a documented cardiovascular diagnosis.

How to Submit a Successful PA for Saxenda to BCBS AZ

A well-structured PA submission reduces the chance of denial. The following framework reflects best practices from obesity medicine specialists and standard PA workflows.

Step 1: Confirm Your Plan Includes an Obesity Drug Benefit

Call the member services number on the back of your BCBS AZ card and ask specifically: "Does my plan include coverage for anti-obesity medications, and is liraglutide (Saxenda) on the formulary?" Some self-funded employer plans carve out obesity drugs entirely, in which case a PA submission will be denied regardless of clinical documentation. Getting a confirmation number and representative name from this call is worthwhile before your prescriber invests time in paperwork.

Step 2: Gather the Right Documentation

Your prescriber's office should compile the following before submitting:

• Office visit notes showing measured BMI within the past 12 months
• Diagnoses with ICD-10 codes (E66.01, E66.09, or E66.3 with a comorbidity code such as I10 for hypertension or E11.9 for type 2 diabetes)
• A three-month or longer behavioral program note from a registered dietitian, certified health coach, or the prescriber's own clinic records showing dietary counseling and physical activity guidance
• Fasting lipid panel, HbA1c, or blood pressure readings that document the comorbidity
• A letter of medical necessity that explicitly cites the FDA-approved indication language and the SCALE trial weight-loss percentages [6]

Step 3: Request Peer-to-Peer Review if Denied

If BCBS AZ denies the initial PA, the prescriber has the right to request a peer-to-peer call with the insurer's medical reviewer, usually within five to seven business days of the denial. During this call, the prescriber can reference the SCALE Obesity and Prediabetes trial data [6] and the Endocrine Society guideline recommendation [3] directly. Peer-to-peer reviews overturn a meaningful share of initial denials without requiring a formal appeal.

Step 4: File a Formal Appeal

If peer-to-peer review fails, a written first-level appeal is the next step. Arizona state law requires that insurers respond to standard first-level appeals within 30 days and expedited appeals within 72 hours when the clinical situation is urgent. Include any new clinical notes, a second opinion from an obesity medicine specialist, and the full peer-reviewed citations for the SCALE trials [6][7].

Cost and Copay Assistance When Coverage Is Denied or Incomplete

Manufacturer Copay Card

Novo Nordisk offers the My$avings Card for Saxenda. Commercially insured patients who are eligible may pay as little as $25 per 28-day supply, subject to a maximum annual savings cap (terms change annually; verify at the Novo Nordisk patient support site). This card cannot be used by Medicare or Medicaid beneficiaries.

340B and Community Health Centers

Patients without insurance coverage who live near a federally qualified health center (FQHC) may access Saxenda at a substantially reduced cost through the 340B Drug Pricing Program. The Health Resources and Services Administration maintains a public database of 340B-covered entities [9].

Therapeutic Alternatives Your Prescriber Might Consider

If Saxenda remains unaffordable or uncovered, your prescriber may consider:

• Semaglutide 2.4 mg (Wegovy), which in the STEP-1 trial (N=1,961) produced 14.9 percent mean weight loss at 68 weeks versus 2.4 percent with placebo [10]. Wegovy may occupy a more favorable formulary tier on some BCBS AZ plans.
• Phentermine/topiramate extended-release (Qsymia), which produced 10.9 percent weight loss at 56 weeks in the EQUIP trial (N=1,267) [11].
• Bupropion/naltrexone extended-release (Contrave), which produced 6.4 percent weight loss at 56 weeks in the COR-I trial (N=1,742) [12].

The 2023 American Gastroenterological Association guideline on pharmacotherapy for adults with obesity notes that all FDA-approved anti-obesity medications produce clinically meaningful weight loss when combined with lifestyle intervention, and that choice of agent should account primarily for individual patient comorbidities and tolerability rather than cost alone when cost barriers can be overcome [13].

Medicare, Medicaid, and ACA Marketplace Plans in Arizona

Medicare Part D

The Medicare Modernization Act of 2003 explicitly excludes drugs used for weight loss from the standard Part D benefit [14]. Saxenda prescribed purely for obesity is therefore not covered under any standard Medicare Part D plan in Arizona. A narrow exception exists if liraglutide is prescribed at the Victoza dose (1.2 to 1.8 mg) for type 2 diabetes, which is a covered indication, but that is a different product and different clinical scenario. Proposed federal legislation has sought to change this exclusion, but as of early 2025, no change has been enacted.

Arizona Medicaid (AHCCCS)

The Arizona Health Care Cost Containment System (AHCCCS) covers some anti-obesity pharmacotherapy for members who meet clinical criteria, but formulary access shifts with each contract year. Members should call AHCCCS directly or ask their managed care organization (for example, UnitedHealthcare Community Plan AZ or Mercy Care) whether liraglutide appears on the current formulary.

ACA Marketplace Plans

ACA marketplace plans in Arizona are not required to cover obesity drugs as an essential health benefit. Coverage depends on the specific issuer and plan metal level chosen. Bronze and silver plans are less likely to include obesity pharmacotherapy than gold or platinum plans. The preventive-care mandate does require coverage of behavioral obesity counseling (the USPSTF recommends intensive multicomponent behavioral intervention for adults with obesity) [15], but that does not extend to prescription drug coverage.

Documenting Comorbidities to Strengthen Your PA

Comorbidity documentation is the single most controllable factor in a PA submission. A prescriber who lists a diagnosis code without supporting lab data gives the insurance reviewer a reason to request more information, which delays the process.

Hypertension Documentation

A blood pressure reading of 130/80 mmHg or above, recorded on two separate visits per the 2017 ACC/AHA hypertension guideline threshold, satisfies the hypertension comorbidity criterion [16]. The note should include the date, actual reading, and the ICD-10 code I10.

Dyslipidemia Documentation

A fasting LDL of 130 mg/dL or above, or triglycerides of 150 mg/dL or above, or HDL below 40 mg/dL in men or below 50 mg/dL in women, supports a dyslipidemia comorbidity under standard clinical criteria [17]. The lab report date should be within 12 months of the PA submission.

Obstructive Sleep Apnea Documentation

A polysomnography report showing an apnea-hypopnea index (AHI) of 5 or above, or a diagnosis letter from a sleep medicine physician, is the standard supporting document. The FDA label for Saxenda does not list sleep apnea as a comorbidity, but BCBS AZ PA criteria have in prior years recognized it under the broader "weight-related comorbidity" language. Confirming this with the specific plan's PA criteria before submission avoids surprises.

What Happens After Saxenda Is Approved

PA approvals for Saxenda are typically granted for 12 months, with a renewal requirement. Renewal criteria at BCBS AZ generally include documented weight loss of at least five percent of initial body weight at 16 weeks. The FDA label states that liraglutide should be discontinued if the patient does not lose at least four percent of baseline body weight after 16 weeks at the 3 mg dose, as continued treatment is unlikely to achieve clinically meaningful weight loss [1]. This four-to-five percent threshold appears in both the FDA label and most BCBS AZ renewal criteria, so weight tracking at 16 weeks is not optional.

The Obesity Medicine Association's clinical practice statement notes that response evaluation at 12 to 16 weeks is standard practice for all anti-obesity pharmacotherapy, and that failure to reach the threshold should prompt a shared decision on dose optimization, addition of behavioral support, or switching agents [18].